The average of price targets set by Wall Street analysts indicates a potential upside of 50.9% in No

Does NovoCure (NVCR) have what it takes to be a top stock pick for momentum investors? Let's find ou

The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in No

Healthcare's defensive demand is strengthening in 2026. BTSG, HRMY, UNH and NVCR stand out on improv

NovoCure (NVCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the co

The mean of analysts' price targets for NovoCure (NVCR) points to a 46.6% upside in the stock. While

Examine the evolution of NovoCure's (NVCR) overseas revenue trends and their effects on Wall Street'

NovoCure remains a Hold as recent gains and operational improvements do not alter its long-term, gli

NovoCure revenue outlook rises after a Q2 beat, stronger patient growth, pipeline progress and plann

Novocure (NVCR) delivered a strong 2Q26 beat, raising full-year guidance to $710–$725 million and ac

Wedbush analyst David Nierengarten maintains NovoCure (NASDAQ:NVCR) with a Neutral and raises the

HC Wainwright & Co. analyst Emily Bodnar maintains NovoCure (NASDAQ:NVCR) with a Buy and rais

US stocks lower, Dow down 0.92%, NASDAQ 2.03% decline. T-Mobile stock falls 5%. NVE Corp up 38%, Nov

Gainers NovoCure (NASDAQ:NVCR) shares moved upwards by 27.7% to $19.88 during Thursday's regula

NovoCure Limited (NVCR) Q2 2026 Earnings Call Transcript

U.S. stocks were down as Dow Jones fell 450 points on Thursday. Lockheed Martin (LMT) shares rose 11

NovoCure (NVCR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimat

NovoCure NASDAQ: NVCR reported record second-quarter 2026 net revenue and active patient levels, wit

NovoCure (NASDAQ:NVCR) released second-quarter financial results and hosted an earnings call on Thur

Gainers Niki BioSolutions (NASDAQ:NIKI) stock moved upwards by 44.7% to $13.01 during Thursday'

Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30,

Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quar

NovoCure (NASDAQ:NVCR) raises FY2026 sales outlook from $690.000 million-$710.000 million to $710.00

NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.13) per share which beat the analyst consens

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnin

NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

NovoCure Limited is downgraded from Strong Buy to Buy after the phase 3 TRIDENT trial failed to meet

NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

The CE Mark is supported by results from the Phase 3 PANOVA-3 trial demonstrating a statistically si

U.S. stocks traded higher on Thursday with the S&P 500 gaining 1% while tech shares surged 2.3%.

US stocks mixed, Dow up 400 pts. Caterpillar, Bandwidth, Everspin, Vistance, IMPINJ, Novocure, Viavi

NovoCure shares rise after PANOVA-4 data show higher disease control and survival signals in metasta

(Editor’s note: The futures prices and ETFs movements were updated in the story) U.S. stock futur